Immix Biopharma, Inc. SEC filings IMMX
Immix Biopharma, Inc. has 244 filings in SEC EDGAR's recent list, going back to Jul 20, 2021. Its latest annual report, Form ARS, was filed on Apr 6, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 30, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 30, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 29, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Other events
|
Jul 20, 2026 | Jul 20, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 29, 2026 | May 22, 2026 |
| 8-K |
Current report
Other events
|
May 21, 2026 | May 21, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 21, 2026 | May 21, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 30, 2026 | Mar 30, 2026 |
| 8-K |
Current report
Material agreement
|
Mar 25, 2026 | Mar 25, 2026 |
| 8-K |
Current report
Material agreement
|
Dec 8, 2025 | Dec 7, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 8, 2025 | Dec 7, 2025 |
| 8-K |
Current report
Other events
|
Nov 26, 2025 | Nov 26, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change
|
Sep 8, 2025 | Sep 5, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 23, 2025 | Jun 20, 2025 |
| 8-K |
Current report
Material agreement
|
Jun 3, 2025 | Jun 3, 2025 |
| 8-K |
Current report
Other events
|
Jul 26, 2024 | Jul 25, 2024 |
| 8-K |
Current report
Auditor change
|
Jul 22, 2024 | Jul 17, 2024 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 14, 2024 | Jun 11, 2024 |
| 8-K |
Current report
Unregistered share sale, Other events
|
May 20, 2024 | May 20, 2024 |
| 8-K |
Current report
Material agreement, Other events
|
Feb 6, 2024 | Feb 6, 2024 |
| 8-K |
Current report
Other events
|
Feb 5, 2024 | Feb 5, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change
|
Aug 22, 2023 | Aug 22, 2023 |
| 8-K |
Current report
Material agreement
|
Jul 14, 2023 | Jul 14, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 8, 2023 | Jun 7, 2023 |
| 8-K |
Current report
Material agreement
|
Mar 22, 2023 | Mar 22, 2023 |
| 8-K/A |
Amended current report
Regulation FD disclosure
|
Mar 13, 2023 | Mar 10, 2023 |
| 8-K |
Current report
Material agreement
|
Mar 13, 2023 | Mar 10, 2023 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Jan 18, 2023 | Jan 12, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 16, 2022 | Dec 16, 2022 |
| 8-K |
Current report
Material agreement, Other events
|
Dec 14, 2022 | Dec 8, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 9, 2022 | Jun 8, 2022 |
| 8-K |
Current report
Other events
|
Jan 19, 2022 | Jan 19, 2022 |
| 8-K |
Current report
Other events
|
Jan 12, 2022 | Jan 12, 2022 |
| 8-K |
Current report
Other events
|
Jan 3, 2022 | Jan 3, 2022 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Dec 20, 2021 | Dec 20, 2021 |
Showing 34 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IMMX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Los Angeles, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1873835
- Former names
- Immix Biopharma, Inc. (until Oct 27, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.